NeoTYPE® DNA & RNA - Brain

Code
NTG-DRBX-02CX
Profile
Active-Compendium
81457x1, 88377x8, 88360x1. Add 81287x1 if ordering MGMT Promoter Methylation Analysis.
81479x1, 88377x8, 88360x1. If sample is insufficient to produce RNA fusion results but DNA SNV/indel and/or CNV results are reported, 81479x1 still applies. If only RNA fusion results are reported, use 81445x1 instead of 81479x1. (SEE NOTES)
Clinical
Oncology,Pathology
FFPE solid tumor tissue: Minimum surface area 10mm2 with 20% tumor content. Please use positively-charged slides and 10% NBF fixative. Do not use zinc fixatives.
Paraffin block: Preferred.
Cut slides: Send 25 unstained sections cut at 5 microns plus one H&E slide (which NeoGenomics will keep). No additional slides are needed if ordering MGMT Promoter Methylation Analysis.
Flag Active
True
Orderable Test Description
The NeoTYPE® DNA & RNA – Brain Profile uses targeted next‑generation sequencing (NGS) to detect single nucleotide variants, insertions/deletions, and gene fusions across <b>83 unique genes (62 DNA and 28 RNA</b>; overlapping targets included). The profile also assesses microsatellite instability <b>(MSI)</b> and tumor mutational burden <b>(TMB)</b>. <br><br>

<b>NGS – SNVs / Indels (62 genes + MSI and TMB)</b><br>
Reflex rule: A microsatellite instability (MSI) NGS result of “indeterminate” will create a reflex to MSI by PCR as long as the tumor percentage is ≥40% and paired normal tissue is available.<br><br>

<b>RNA Fusions (28 genes)</b><br><br>

<b>FISH – CNVs (9)</b><br>
1p/19q co‑deletion, +7/‑10 (trisomy 7, monosomy 10), CDKN2A (p16) deletion, EGFR amplification, MET amplification, MYCN amplification, PDGFRA amplification, PTEN deletion<br>
(FISH is global only)<br><br>

<b>IHC (1 biomarker)</b><br>
PD‑L1 LDT (tech‑only available)<br><br>

<b>Test customization:</b><br>
MGMT Promoter Methylation Analysis by PCR<br><br>

<b>Legacy Test information: </b><br>
As of May 12, 2025, this test serves as replacement for the following test(s) that are no longer offered:<br>
* Brain NGS Fusion Panel</p>
Orderable Turn Around Time
14 Days
Meta Description
<p>NeoTYPE&reg; DNA &amp; RNA Brain is a targeted NGS profile for CNS tumors that detects key biomarkers and immuno-oncology targets.</p>
NY Approved
True
Orderable Biomarkers JSON
{"DNA Sequencing": {"SNVs + Indels": ["AKT1", "APC", "ATRX", "BAP1", "BCOR", "BCORL1", "BRAF", "CDK6", "CDKN2A", "CDKN2B", "CIC", "CTNNB1", "DICER1", "EED", "EGFR", "EPCAM", "ERBB2", "ERBB4", "FGFR1", "FGFR2", "FGFR3", "FUBP1", "GNA11", "GNAQ", "H3-3A", "H3C3", "HRAS", "IDH1", "IDH2", "KDM6A", "KRAS", "MAP2K1", "MET", "MLH1", "MSH2", "MSH6", "MYC", "MYCN", "NF1", "NF2", "NOTCH1", "NRAS", "PDGFRA", "PIK3CA", "PMS2", "PTCH1", "PTEN", "RB1", "SETD2", "SF3B1", "SMAD4", "SMARCA4", "SMARCB1", "SMO", "SRC", "SUFU", "SUZ12", "TERT", "TP53", "TSC1", "TSC2", "VHL"], "Genomic Signatures": ["MSI", "TMB"], "Promoter Methylation": ["MGMT"]}, "RNA Sequencing": {"Fusions": ["ALK", "BRAF", "CIC", "EGFR", "EML4", "ETV6", "EWSR1", "FGFR1", "FGFR2", "FGFR3", "FUS", "KIAA1549", "MAML2", "MET", "MN1", "MYB", "MYBL1", "NTRK1", "NTRK2", "NTRK3", "PRKCA", "RAF1", "ROS1", "STAT6", "TACC3", "TFG", "YAP1", "ZFTA"], "Splice Variant": ["EGFR"]}, "Immunohistochemistry (IHC)": {"Expression": ["PD-L1"]}, "Fluorescence In Situ Hybridization (FISH)": {"Amplification(s)": ["EGFR", "MET", "MYCN", "PDGFRA"], "Deletion(s)": ["1p19q", "p16", "PTEN"], "Trisomy": ["Chromosome 7"], "Monosomy": ["Chromosome 10"]}}
Keywords string
CNS, WHO, medulloblastoma, embryonal, cytoma, astrocytoma, glioma, glioneuronal, ependymoma, meningioma, pharyngioma, Brain NGS Fusion Panel NeoTYPE® DNA & RNA - Brain
Title URL
neotype-dna-rna-brain
TAT Details

NGS: 14 Days
FISH: 7 Days
IHC: Global: 2 Days
          Tech-Only (stain
          only): 24 Hours
Potential Reflex Testing (Additional Time):
MSI by PCR: 5 Days

EHR Integrations
Storage and transportation
Use cold pack for transport, making sure cold pack is not in direct contact with specimen. NYS clients please provide date and time of Collection.